GLP-1-based therapy for diabetes: what you do not know can hurt you.
about
Regulation of glucose homeostasis by GLP-1In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage productsChronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemiaAcute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.Optical control of insulin release using a photoswitchable sulfonylureaThe dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications.Glucagon like peptide-1 receptor expression in the human thyroid glandRelative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.Interpreting adverse signals in diabetes drug development programs.Mechanisms behind the immediate effects of Roux-en-Y gastric bypass surgery on type 2 diabetesPSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist.Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.A cohort study of acute pancreatitis in relation to exenatide use.Coming full circle in diabetes mellitus: from complications to initiation.Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013.Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.Incretins: their physiology and application in the treatment of diabetes mellitus.An updated review on cancer risk associated with incretin mimetics and enhancers.Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan.[6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hypergRhGLP-1 (7-36) protects diabetic rats against cerebral ischemia-reperfusion injury via up-regulating expression of Nrf2/HO-1 and increasing the activities of SOD.The evolving world of GLP-1 agonist therapies for type 2 diabetes.Prescribing gliptins: Enthusiasm should be coupled with caution.GLP-1 receptor agonist effects on normal and neoplastic pancreata.GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Sustained treatment with a stable long-acting oxyntomodulin analogue improves metabolic control and islet morphology in an experimental model of type 1 diabetes.Circulating MicroRNAs in Elderly Type 2 Diabetic Patients.
P2860
Q24563430-348130C4-7680-4723-A93D-2CF5DAAE6CDEQ28543699-221C23FE-93BC-442F-B4ED-FBB96F0EB1FAQ30513617-C7158201-8C8C-41A6-84F0-1A4B43BDD36BQ34041974-3F3D0F06-B0A4-4787-B4F7-414897D4F0FFQ34237350-04F45534-3ACF-4529-ABDC-78967D03F3D5Q34397447-F4C20E8F-2402-4AB7-8A86-487BB7EE08A7Q35022184-5BB415BA-CF2C-440A-89B7-739E3DAE5637Q35087846-2BCAF34D-AAB1-4588-B8DE-3996F349E9B2Q36141532-EA1466AA-466F-4912-80B2-C7D97404FCD1Q36420499-C5032685-B191-44B8-AD06-3A9A2DDA3BE2Q36942266-B20B7733-721A-4E81-AB7E-743F5A818F80Q37053538-DDB3F22D-A2FA-4A7F-AFE4-5F5387EB46B0Q37428774-CA5B7C04-5F51-4DE4-BEAE-C6ED48202612Q37446672-8E0B880C-96FC-456F-A502-611B50438AC7Q37841739-26F7096F-EA0D-4CEA-8E9F-7CACDE5947F2Q38072272-40194D57-FF24-4CF2-AA50-DD0E07736CB0Q38089327-9D726259-2399-4E83-AE2C-C6A5FBE8CB33Q38101993-59302D40-5180-4AC2-A4C7-A48B07C5F54FQ38225693-9C06D062-E77D-485F-8ACF-9B014B94DC42Q38388920-1880D130-97A5-4DAB-B718-DCE357091C3DQ40478079-1AB431B1-5DB9-4926-9FA5-E8A020126EAAQ41336715-425E6C6B-31D4-4780-A5CD-CCAB5F456EC2Q41636096-F92CC78E-8691-4961-83A3-132F873520A8Q42054096-4D9936F1-0007-4529-81E6-5EAF6A6F1C9CQ42280018-B43303D8-C271-4D03-B593-1BCA082DC820Q42536295-323CABEC-DC91-46C6-BB06-BEFED0C3D2FCQ42536351-ADE7742E-3D82-4FC0-9965-15B0BE14AAE2Q45778975-CF4D489D-F079-4016-B4A1-9C9828D16351Q53836936-1F41A94E-4797-4E4B-99C3-7081C5F431D3Q55000266-7B80B901-B5AC-440C-990D-CB9B0F96625C
P2860
GLP-1-based therapy for diabetes: what you do not know can hurt you.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
GLP-1-based therapy for diabetes: what you do not know can hurt you.
@en
GLP-1-based therapy for diabetes: what you do not know can hurt you.
@nl
type
label
GLP-1-based therapy for diabetes: what you do not know can hurt you.
@en
GLP-1-based therapy for diabetes: what you do not know can hurt you.
@nl
prefLabel
GLP-1-based therapy for diabetes: what you do not know can hurt you.
@en
GLP-1-based therapy for diabetes: what you do not know can hurt you.
@nl
P2860
P356
P1433
P1476
GLP-1-based therapy for diabetes: what you do not know can hurt you.
@en
P2093
Peter C Butler
P2860
P304
P356
10.2337/DC09-1902
P407
P577
2010-02-01T00:00:00Z